A systematic literature review of the epidemiology, quality of life, and economic burden, including disease pathways and treatment patterns of relapsed/refractory classical Hodgkin lymphoma-Reference-Cited by-同舟云学术

A systematic literature review of the epidemiology, quality of life, and economic burden, including disease pathways and treatment patterns of relapsed/refractory classical Hodgkin lymphoma

Published:2022-07-03 Issue:7 Volume:15 Page:607-617
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Raut Monika¹,Singh Gautamjeet²,Hiscock Immaculata¹,Sharma Sheetal²,Pilkhwal Nameeta²

Affiliation:

1. CORE Oncology, Merck & Co Inc, Kenilworth, NJ, USA

2. Regulatory and Access, Parexel International, Mohali, India

Funder

Merck & Co., Inc

Publisher

Informa UK Limited

Subject

Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2022.2080050

Reference66 articles.

1. Hodgkin lymphoma

2. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

3. GLOBOCAN. GLOBOCAN 2018: estimated cancer incidence, mortality, and prevalence worldwide in 2018. Available from: https://gco.iarc.fr/today/online-analysis-table?v=2018&mode=population&mode_population=countries&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=1&include_nmsc_other=1. Cited 2021 Apr 21.

4. National cancer institute: Surveillance epidemiology, and end results program (SEER). 2021. Cancer stat facts: Hodgkin lymphoma. Available from: https://seer.cancer.gov/statfacts/html/hodg.html. Cited 2021 Apr 21.

5. Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single‐cell RNA sequencing of pediatric Hodgkin lymphoma to study the inhibition of T cell subtypes;HemaSphere;2024-09

2. Management of Peripheral Neuropathy Associated with Brentuximab Vedotin in the Frontline Treatment of Classical Hodgkin Lymphoma;Critical Reviews in Oncology/Hematology;2024-09

3. Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review;PharmacoEconomics;2024-04-14

4. Patient-reported outcomes in Hodgkin lymphoma trials: a systematic review;Frontiers in Oncology;2024-03-13